Relationship of HPV16 E6 seropositivity with circulating tumor tissue modified HPV16 DNA before head and neck cancer diagnosis

Oral Oncology, Год журнала: 2023, Номер 141, С. 106417 - 106417

Опубликована: Май 4, 2023

Язык: Английский

---

The molecular characteristics of recurrent/metastatic HPV‐positive head and neck squamous cell carcinoma: A systematic review of the literature

Clinical Otolaryngology, Год журнала: 2024, Номер 49(4), С. 384 - 403

Опубликована: Апрель 24, 2024

Abstract Objectives About 17% of patients with human papillomavirus (HPV)‐positive head and neck squamous cell carcinoma (HNSCC), which is mainly comprised oropharyngeal SCC (OPSCC), will experience disease recurrence, often considered incurable when manifested at a metastatic and/or recurrent stage. We conducted critical qualitative systematic review. Our objectives were to provide an overview the molecular landscape recurrent/metastatic HPV‐positive HNSCC as well novel biomarkers. Design A literature review was identify studies reporting on characteristics HNSCC, biomarkers treatment options. The reviews abstracts, full articles, revision included studies, followed by data extraction quality assessment performed three independent assessors. All primary literature, such retrospective, prospective, clinical trials basic research considered, final search end February 2023. level evidence rated using guidelines published Oxford Centre for Evidence‐based Medicine assessed Newcastle‐Ottawa Scale criteria. Results Conclusions resulted in identification 1991 articles. total 181 articles screened, 66 this analysis. Several reported that had higher rates TP53 mutation genomically similar HPV‐negative HNSCC. detection circulating tumour tissue‐modified HPV DNA (ctHPVDNA) specific biomarker has shown promising results monitoring response recurrence subset In addition, targeted therapy emerged, including agents inhibit overexpressed EGFR . Studies combination immunotherapy are also underway. outlines latest distinct profiles potential ctHPVDNA testing routine practice. More controlled longitudinal needed additional targets assess performance benefits

Язык: Английский

---

Tumor-Derived Exosomes and the Role of Liquid Biopsy in Human Papillomavirus Oropharyngeal Squamous Cell Carcinoma

The Cancer Journal, Год журнала: 2023, Номер 29(4), С. 230 - 237

Опубликована: Июль 1, 2023

The global incidence of human papillomavirus-positive (HPV+) head and neck squamous cell carcinoma (HNSCC) has surged in recent decades, with HPV+ HNSCC accounting for >70% oropharynx cancers the United States. Its men surpassed that cervical cancer women, reliable assays are needed early detection to monitor response therapy. Human OPSCC a more favorable therapy prognosis than HPV-negative (HPV-) HNSCC, motivating regimens deintensify curative surgery or chemoradiotherapy protocols. A barrier deintensifying personalizing is lack predictive biomarkers. Furthermore, HPV- survival rates static without surveillance biomarkers available. emergence circulating plasma-based reflecting tumor-immune microenvironment heralds new era diagnosis We review evidence on tumor-derived extracellular vesicles (exosomes) as diagnosis, prognostication, treatment HNSCC.

Язык: Английский

---

Circulating Tumor HPV DNA in Patients With Head and Neck Carcinoma

The American Journal of Surgical Pathology, Год журнала: 2023, Номер 48(1), С. 80 - 87

Опубликована: Сен. 27, 2023

Circulating tumor human papillomavirus DNA (ctHPVDNA) testing using digital-droplet polymerase chain reaction (PCR) detects fragments of tumor-modified (HPV) in the plasma patients with HPV-associated head and neck squamous cell carcinomas (HNSCCs). Its impact on surveillance primary diagnosis is limited by unresolved issues relating to sensitivity specificity. The study population consisted HNSCC who had undergone ctHPVDNA testing. HPV status was determined p16 immunohistochemistry PCR-HPV genotyping samples. For discrepant cases (HPV-positive/ctHPVDNA-negative), confirmed RNA situ hybridization and, when possible, targeted single-nucleotide polymorphisms genotyping. A total 167 testing, 141 tumors were positive PCR Genotypes included types 16 (91.5%), 33 (4.3%), 35 (2.1%), 18 (2.1%). detected 133 (94.3%) HPV-positive HNSCCs but none HPV-negative HNSCCs. Four 5 p16-positive that negative hybridization, 2 these cases, rare high-risk genotypes identified. a 91.7%, specificity 100%, predictive value 63.6%. likelihood have detectable high. Non-HPV16 contribute discrepancies only small subset cases. This finding validates ongoing efforts use as tool, even diagnostic assay presenting masses and/or oropharynx.

Язык: Английский

---

The Clinical Utility of Circulating HPV DNA Biomarker in Oropharyngeal, Cervical, Anal, and Skin HPV-Related Cancers: A Review

Pathogens, Год журнала: 2023, Номер 12(7), С. 908 - 908

Опубликована: Июль 5, 2023

Human papillomavirus (HPV) is recognized as being related to a wide variety of known cancers: cervical, oropharyngeal, anal, vaginal, penile, and skin. For some these cancers, rigorous algorithms for screening, therapeutical interventions, follow-up procedures have been established. Vaccination using the nonvalent anti-HPV vaccine, which prevents infection regarding most frequently involved high-risk HPV types (16, 18, 31, 33, 45, 52, 58) low-risk (6 11), has also extensively prevented, controlled, even eradicated infections. Still, with all multidisciplinary burden cancers still high worldwide. The circulating DNA HPV-induced thought be an adequate biomarker optimizing control virus-related cancers. We analyzed literature published in last 5 years ctDNA four above-mentioned used assay detection was droplet digital PCR assay, management therapy late stages cancer. could not early any studied OPSCCs were frequent via assays. Larger, properly designed cohort studies might establish clinical utility this biomarker.

Язык: Английский

---